Oculis Reports Q3 2023 Financial Results and Provides Company Update
GlobeNewswire
· Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain..
· Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain..
· LEOPARD trial initiation follows recent positive data from OCS-01 eye drops from the Stage 1 Phase 3 DIAMOND trial in patients..
*GOTHENBURG, SE / ACCESSWIRE / November 15, 2022 / *IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, November 15,..